바이오시뮬레이션 시장 : 오퍼링, 딜리버리 모델, 애플리케이션, 최종사용자별 - 세계 예측(2025-2030년)

The Biosimulation Market was valued at USD 3.10 billion in 2023 and is projected to grow to USD 3.55 billion in 2024, with a CAGR of 14.60%, reaching USD 8.07 billion by 2030.

Biosimulation has emerged as a vital tool that is reshaping the life sciences landscape. This discipline blends advanced computational algorithms with biological data to streamline and enhance research activities, offering a more precise and cost-effective alternative to traditional experimental procedures. Today, innovative organizations are leaning into systems that can predict outcomes, simulate drug interactions, and optimize clinical trial designs. By leveraging sophisticated simulation tools, the market is witnessing accelerated development cycles, improved decision-making, and reduced risk in drug discovery and development. The proliferation of digital technologies and increased demand for efficient research methodologies have propelled biosimulation into the spotlight as a key enabler for overcoming scientific and financial hurdles. In this environment, the fusion of predictive analytics with complex biological models is proving indispensable in advancing both preclinical and clinical studies. With the industry increasingly leaning on data-driven strategies, today's biosimulation strategies pave the way for breakthroughs that hold the potential to transform patient care and elevate industry standards across the globe.

Transformative Shifts in the Biosimulation Landscape

The biosimulation landscape is undergoing profound transformations, fueled by rapid technological advancements and a paradigm shift in research methodologies. Traditional laboratory experiments are gradually making way for digital and computational alternatives that offer not only speed but also a greater depth of analysis. The integration of automation, machine learning, and high-fidelity simulation models is empowering researchers to explore complex biological phenomena with unprecedented clarity. These transformative shifts are characterized by a move from reliance on empirical data collection towards predictive modeling, enabling faster hypothesis testing and more informed decision-making. Moreover, the evolution of simulation platforms is providing versatile tools that cater to the unique requirements of various aspects of pharmaceutical research. As a result, the industry is embracing a more agile framework where iterative design and virtual testing are not just complementary activities, but central to the operational blueprint. The changes in regulatory perspectives and the growing acceptance of digitally simulated outcomes further underline this transition, making biosimulation an increasingly integral part of modern therapeutic innovation and research.

In-Depth Analysis of Biosimulation Segmentation and Its Implications

The market is segmented in multiple ways which offer a window into the sophisticated layers of biosimulation. When viewed based on the offering, the market divides into services and software, where services are further broken down into contract services and in-house services, whereas the software category encompasses a range of specialized tools including molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, toxicity prediction software, and trial design software. Another dimension is based on the delivery model, which distinguishes between ownership models and subscription models, reflecting varied investment strategies and access preferences. Moreover, application-based segmentation highlights the dual focus on drug development and drug discovery. Drug development itself spirals into nuances such as clinical trials and preclinical testing, with the latter further delineated into ADME/Tox and PK/PD considerations. In contrast, drug discovery emphasizes techniques such as lead identification and optimization alongside target identification and validation. Lastly, segmentation based on end-user categorizes the market according to contract research organizations, pharmaceutical and biotechnology companies, regulatory authorities, and research institutes, each playing their distinct role in driving the biosimulation value chain.

Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.

Based on Delivery Model, market is studied across Ownership Models and Subscription Models.

Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.

Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.

Regional Dynamics Shaping the Global Biosimulation Market

Regional insights reveal a complex mosaic of opportunities and challenges that are reshaping the biosimulation arena. In the Americas, a blend of strong research institutions and robust funding mechanisms fosters an environment where biosimulation tools are rapidly adopted and refined. The region stands out with its strong regulatory frameworks and strategic partnerships that spearhead innovation. In the Europe, Middle East & Africa region, the convergence of academic research and industrial expertise creates a vibrant ecosystem. Here, well-established pharmaceutical hubs collaborate with technology providers to drive efficiency and bolster regulatory compliance, ensuring that simulation technologies align with regional standards. Meanwhile, the Asia-Pacific region is witnessing significant growth fueled by increasing investments in research and development, a surge in tech-driven startups, and expanding capabilities in digital health. This geographically diverse spread of opportunities underscores the need for tailored strategies that cater to local market dynamics, competitive pressures, and intercultural variations in research methodologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Industry Leaders Driving Biosimulation Innovation

Industry insights highlight the emergence of several key players who are instrumental in advancing the field of biosimulation. Leaders such as Advanced Chemistry Development, Inc. and Aitia are at the forefront of integrating computational modeling into everyday research routines. Companies like Allucent, Biomed Simulation, Inc., and BioSimulation Consulting Inc. bring specialized expertise that enhances the scope and precision of simulation strategies employed throughout the sector. This is complemented by the innovation drive of Cadence Design Systems, Inc., Cell Works Group, Inc., and Certara, Inc., along with Chemical Computing Group ULC and Crystal Pharmatech Co., Ltd. Additional trailblazers including Cytel Inc., Dassault Systemes SE, ICON PLC, and In Silico Biosciences, Inc. are redefining industry benchmarks. INOSIM Software GmbH, Instem PLC, Model Vitals, and Physiomics PLC, among others like Quotient Sciences Limited, Resolution Medical, and Schrodinger, Inc., further bolster the competitive landscape. The influence of companies such as Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation cannot be overstated in the ongoing drive towards more efficient, reliable, and transformative biosimulation methodologies.

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Crystal Pharmatech Co., Ltd., Cytel Inc., Dassault Systemes SE, ICON PLC, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation. Strategic Recommendations for Biosimulation Industry Leaders

For industry leaders, the evolving landscape presents multiple avenues for strategic advancement. It is imperative to invest in next-generation simulation platforms that blend advanced computational power with intuitive user interfaces, thereby enhancing both predictive accuracy and operational efficiency. Fostering partnerships with technology providers can facilitate access to innovative tools while also offering new collaborative research opportunities. Leaders should prioritize dynamic talent development programs that not only cultivate expertise in simulation technologies but also encourage cross-disciplinary synergy between data science, biology, and regulatory affairs. Embracing flexible engagement models such as subscription-based solutions may reduce upfront costs and stimulate broader adoption of emerging technologies. In addition, benchmarking against industry pioneers and integrating real-world data analytics into simulation frameworks can significantly improve overall performance. These actionable approaches offer a roadmap for capitalizing on the transformative potential of biosimulation, ensuring that organizations remain agile, competitive, and well-equipped to address rapidly evolving market requirements.

Conclusion: The Future of Biosimulation in a Rapidly Evolving Landscape

In summary, the biosimulation market is positioned at a critical juncture where technological innovation and strategic foresight converge to redefine research paradigms. The shift from conventional experimental models to data-driven simulation techniques underscores the importance of adaptability and proactive investment in advanced methodologies. A detailed segmentation analysis reveals the multifaceted nature of the market, spanning various offerings, delivery models, applications, and end-users. This complexity is further complemented by distinct regional dynamics and the presence of pioneering companies whose innovative endeavors are setting new industry benchmarks. The insights gained from examining these factors converge to offer a comprehensive understanding of the current state and future trajectory of biosimulation. Ultimately, the key to sustained success in this rapidly evolving field lies in the ability to harness technological advancements, nurture collaborative ecosystems, and maintain a steadfast commitment to continuous improvement and operational excellence.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing emphasis on research of personalized medicine
    • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
    • 5.1.3.2. Rising investments for drug developments and drug testings
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
  • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation owing to its lower initial costs
  • 5.2.3. Application: Increasing application of biosimulation for clinical trials
  • 5.2.4. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biosimulation Market, by Offering

• 6.1. Introduction
• 6.2. Services
  • 6.2.1. Contract Services
  • 6.2.2. In-House Services
• 6.3. Software
  • 6.3.1. Molecular Modeling & Simulation Software
  • 6.3.2. PBPK Modeling & Simulation Software
  • 6.3.3. PK/PD Modeling & Simulation Software
  • 6.3.4. Toxicity Prediction Software
  • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

• 7.1. Introduction
• 7.2. Ownership Models
• 7.3. Subscription Models

8. Biosimulation Market, by Application

• 8.1. Introduction
• 8.2. Drug Development
  • 8.2.1. Clinical Trials
  • 8.2.2. Preclinical Testing
    • 8.2.2.1. ADME/Tox
    • 8.2.2.2. PK/PD
• 8.3. Drug Discovery
  • 8.3.1. Lead Identification & Optimization
  • 8.3.2. Target Identification & Validation

9. Biosimulation Market, by End-User

• 9.1. Introduction
• 9.2. Contract Research Organizations
• 9.3. Pharmaceutical & Biotechnology Companies
• 9.4. Regulatory Authorities
• 9.5. Research Institutes

10. Americas Biosimulation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biosimulation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. ProductLife Group enhances drug development capabilities with IntiQuan acquisition for innovative biosimulation solutions
  • 13.3.2. Cytel's new East Horizon platform enhances adaptive trial design with cloud integration
  • 13.3.3. Orion and Aitia leverage AI-driven digital twins to revolutionize drug discovery in oncology sector
  • 13.3.4. Biosimulation and tumor microenvironment modeling enhance precision of immunotherapy predictions for NSCLC patients
  • 13.3.5. Quantum breakthroughs in biosimulation revolutionize drug discovery with cutting-edge precision modeling
  • 13.3.6. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
  • 13.3.7. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
  • 13.3.8. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
  • 13.3.9. ZETA Group acquires majority stake in INOSIM to revolutionize simulation and engineering in biopharma industry
  • 13.3.10. Innovative cloud-based biosimulation partnership between Exploristics and Exonate revolutionizes clinical trial design for retinal disease therapies
  • 13.3.11. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Simulations Plus, Inc.
  • 13.4.2. Cadence Design Systems, Inc.
  • 13.4.3. Dassault Systemes SE
  • 13.4.4. Certara, Inc.
  • 13.4.5. Thermo Fisher Scientific Inc.

Companies Mentioned

• 1. Advanced Chemistry Development, Inc.
• 2. Aitia
• 3. Allucent
• 4. Biomed Simulation, Inc.
• 5. BioSimulation Consulting Inc.
• 6. Cadence Design Systems, Inc.
• 7. Cell Works Group, Inc.
• 8. Certara, Inc.
• 9. Chemical Computing Group ULC
• 10. Crystal Pharmatech Co., Ltd.
• 11. Cytel Inc.
• 12. Dassault Systemes SE
• 13. ICON PLC
• 14. In Silico Biosciences, Inc.
• 15. INOSIM Software GmbH
• 16. Instem PLC
• 17. Model Vitals
• 18. Physiomics PLC
• 19. Quotient Sciences Limited
• 20. Resolution Medical
• 21. Schrodinger, Inc.
• 22. Simulations Plus, Inc.
• 23. Thermo Fisher Scientific Inc.
• 24. VeriSIM Life
• 25. VIRTUALMAN
• 26. Yokogawa Electric Corporation